KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Research & Development (2016 - 2025)

Historic Research & Development for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Research & Development rose 3525.36% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.7 million, marking a year-over-year increase of 4203.85%. This contributed to the annual value of $210.4 million for FY2024, which is 2559.94% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Research & Development is $77.1 million, which was up 3525.36% from $75.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Research & Development ranged from a high of $77.1 million in Q3 2025 and a low of $16.3 million during Q1 2021
  • Its 5-year average for Research & Development is $40.7 million, with a median of $41.1 million in 2023.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Research & Development skyrocketed by 10411.16% in 2023, and later surged by 1198.0% in 2024.
  • Over the past 5 years, Xenon Pharmaceuticals' Research & Development (Quarter) stood at $21.9 million in 2021, then soared by 59.14% to $34.8 million in 2022, then increased by 17.93% to $41.1 million in 2023, then surged by 44.79% to $59.5 million in 2024, then increased by 29.56% to $77.1 million in 2025.
  • Its last three reported values are $77.1 million in Q3 2025, $75.0 million for Q2 2025, and $61.2 million during Q1 2025.